The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
-
Paragraph 0457-0458
(2021/11/13)
Novel protein inhibitor and preparation method and application thereof
The invention provides a novel protein inhibitor and a preparation method and application thereof, and specifically provides a compound as shown in a formula I, wherein definitions of all groups are described in the specification. The compound has good Bcl-2 family protein inhibition activity and can be used for preparing a series of medicines for treating diseases related to Bcl-2 family proteinactivity.
-
Paragraph 0120; 0123
(2019/11/12)
ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS
Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.
-
Paragraph 0284; 0285
(2017/07/14)
Organocatalytic, Enantioselective Synthesis of 1- and 3-Substituted Isochromans via Intramolecular Oxa-Michael Reaction of Alkoxyboronate: Synthesis of (+)-Sonepiprazole
The enantioselective oxa-Michael reaction of alkoxyboronate strategy was demonstrated to provide a new and practical route to enantioriched 1- and 3-substituted isochromans using a chiral bifunctional organocatalyst. Furthermore, this methodology was exte
Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
-
Page/Page column 33-34
(2008/06/13)
External chiral ligand-induced enantioselective lithiation/S(E)2 reactions of isochroman and phthalan
Treatment of isochroman and phthalan with a t-BuLi/chiral bis(oxazoline) complex followed by reaction with carbon-electrophiles such as benzaldehyde and CO2 is shown to afford the α-substituted derivatives in moderate-to-high enantioselectivities (up to 97% ee and 83% ee, respectively). The asymmetric induction is proved to occur at the post-lithiation step. (C) 2000 Elsevier Science Ltd.
Tomooka,Wang,Okazaki,Nakai
p. 6121 - 6125
(2007/10/03)
Heterocyclic compounds for the treatment of CNS and cardiovascular disorders
Novel aromatic bicyclic amines of formula (I) STR1 are useful in treating central nervous system disorders and cardiac arrhythmias and cardiac fibrillation.
-
(2008/06/13)
IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES
The present invention relates to imidazo[1,2-a]pyridine compounds of formula (1) STR1 which are dopamine D-4 antagonists and useful as anti-psychotic agents.
-
(2008/06/13)
More Articles about upstream products of 170856-87-8